Schalper, Kurt A. http://orcid.org/0000-0001-5692-4833
Carleton, Michael
Zhou, Ming http://orcid.org/0000-0003-4101-3185
Chen, Tian
Feng, Ye
Huang, Shu-Pang
Walsh, Alice M. http://orcid.org/0000-0001-5905-5768
Baxi, Vipul
Pandya, Dimple
Baradet, Timothy
Locke, Darren
Wu, Qiuyan
Reilly, Timothy P.
Phillips, Penny
Nagineni, Venkata
Gianino, Nicole
Gu, Jianlei
Zhao, Hongyu http://orcid.org/0000-0003-1195-9607
Perez-Gracia, Jose Luis
Sanmamed, Miguel F.
Melero, Ignacio http://orcid.org/0000-0002-1360-348X
Funding for this research was provided by:
Ministerio de Economía y Competitividad (SAF2017-83267-C2-1-R)
Article History
Received: 27 July 2019
Accepted: 25 March 2020
First Online: 11 May 2020
Competing interests
: I.M. reports receiving commercial research grants from Bristol-Myers Squibb, Bioncotech, Alligator, AstraZeneca and Roche; has received speakers bureau honoraria from MSD; and is a consultant/advisory board member for Bristol-Myers Squibb, Roche, Genmab, F-Star, Bioncotech, Bayer, Numab, Alligator, Boehringer Ingelheim and AstraZeneca. K.A.S. reports receiving research funding from Genoptix/Navigate (Novartis), Vasculox/Tioma, Tesaro, Moderna Therapeutics, Takeda, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol-Myers Squibb, AstraZeneca and Eli Lilly; has received consultant/advisory board fees from Celgene, Moderna Therapeutics, Shattuck Labs, Pierre-Fabre, AbbVie, AstraZeneca, EMD Serono, Ono Pharmaceuticals, Clinica Alemana de Santiago, Dynamo Therapeutics, Torque Therapeutics, Agenus and Takeda; and has received speaker honoraria and/or travel support for meetings from Takeda, Merck, Bristol-Myers Squibb, Fluidigm, Peerview, Biotrac, Cambridge Healthtech Institute, Shattuck Labs and Genentech. J.L.P.-G. reports grants, personal fees and nonfinancial support from Roche, Bristol-Myers Squibb and MSD; and reports grants and personal fees from Ipsen and Eisai, and grants from Incyte and Janssen. M.C., M.Z., S.-P.H., T.C. and Y.F. have a patent (‘Combination Therapy with Anti-IL-8 Antibodies and Anti-PD-1 Antibodies for Treating Cancer’, publication number WO 2019140150). T.P.R. is a co-inventor in a provisional patent application (application number 62/650047) regarding the use of anti-IL-8 and anti-PD1 for the treatment of cancer. M.C., M.Z., T.C., Y.F., S.-P.H., A.M.W, V.B, D.P., T.B., D.L., T.P.R., P.P., J.G. and H.Z. are current or former employees of Bristol-Myers Squibb, which is developing anti-IL-8 (NCT03400332). T.P.R., A.M.W., D.L. and S.-P.H. own stock in Bristol-Myers Squibb. None of the remaining authors have relevant conflicts of interest to report.